We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
From May 2023 to May 2024
Stifel 2023 Immunology and Inflammation Virtual Summit Fireside Chat: Wednesday, September 20th at 10:15 am ETPresenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Virtual
Jefferies Cell & Genetic Medicine SummitFireside Chat: Tuesday, September 26th at 9:00 am ETOne-on-one meetings: September 26th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York
2023 Cantor Global Healthcare ConferencePresentation: Wednesday, September 27th at 9:10 am ETOne-on-one meetings: September 27th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York
Webcast of the presentations will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event.
About Gracell Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-cell non-Hodgkin's lymphoma and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
Media contact Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong@gracellbio.com
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
